EXHIBIT 32.1

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities
Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of
the United States Code (18 U.S.C. Section 1350), Henry J. Fuchs, M.D., the
President and Chief Executive Officer of IntraBiotics Pharmaceuticals, Inc. (the
"Company"), and David J. Tucker the Principal Financial Officer of the Company,
each hereby certifies that, to his knowledge:

1. The Company's Quarterly Report on Form 10-Q for the period ended March 31,
2004, to which this Certification is attached as Exhibit 32.1 (the "Periodic
Report"), fully complies with the requirements of Section 13(a) or Section 15(d)
of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Periodic Report fairly presents, in all
material respects, the financial condition of the Company at the end of the
periods covered by the Periodic Report and the results of operations of the
Company for the periods covered by the Periodic Report.

This certification accompanies the Form 10-Q to which it relates and shall not
be deemed "filed" by the Company for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended (whether made before or after
the date of the Form 10-Q), irrespective of any general incorporation language
contained in such filing.

In Witness Whereof, the undersigned have set their hands hereto as of the 12th
day of November, 2004.

/s/ Henry J. Fuchs                                /s/ David J. Tucker
- --------------------------                        ------------------------------
Henry J. Fuchs, M.D.                              David J. Tucker
President and Chief Executive Officer             Principal Financial Officer

A signed original of this written statement required by Rule 13a-14(b) of the
Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of
Title 18 of the United States Code has been provided to IntraBiotics
Pharmaceuticals, Inc. and will be retained by IntraBiotics Pharmaceuticals, Inc.
and furnished to the Securities and Exchange Commission or its staff upon
request.